title: [Assessment of bone quality. Bone quality and osteoporosis treatment].
abstract: Anti-resorptive agents are useful for prevent osteoporotic fractures in postmenopausal women because they protect bone architecture. However, long duration of strong suppression of bone resorption may cause severe suppressed bone turnover, which results in reduced bone material properties such as homogenous distribution of mineralization or increased microdamage accumulation. Appropriate suppression of bone remodeling is a key for anti-resorptive treatments of osteoporosis to maintain or improve bone quality.
authors.affiliation: Kagawa University, Faculty of Medicine, Department of Orthopedic Surgery.
authors.forename: Tasuku
authors.initials: T
authors.lastname: Mashiba
mesh_terms: D000375:Aging / Q000378:metabolism / Q000473:pathology; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D016723:Bone Remodeling / Q000187:drug effects* / Q000502:physiology*; D001862:Bone Resorption / Q000188:drug therapy / Q000209:etiology; D001842:Bone and Bones / Q000378:metabolism* / Q000473:pathology*; D002113:Calcification, Physiologic; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000209:etiology; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride